GRAIL spotlights Galleri’s “more than 200 cancers” data ahead of two major October conferences
Market Chameleon (Tue, 6-Oct 7:07 AM)
GRAL jumps as FDA panel backs Galleri, with a 7–2 benefit-risk vote and unanimous safety support
Market Chameleon (Thu, 24-Sep 11:03 AM)
FDA panel backs GRAIL’s Galleri, with a 7–2 vote that benefits outweigh risks
Market Chameleon (Thu, 24-Sep 7:30 AM)
